Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis

Abstract Background Bruton’s tyrosine kinase (BTK) is a key signaling node in B cell receptor (BCR) and Fc receptor (FcR) signaling. BTK inhibitors (BTKi) are an emerging oral treatment option for patients suffering from multiple sclerosis (MS). Remibrutinib (LOU064) is a potent, highly selective co...

Full description

Bibliographic Details
Main Authors: Barbara Nuesslein-Hildesheim, Enrico Ferrero, Cindy Schmid, Catherine Huck, Paul Smith, Sarah Tisserand, Joelle Rubert, Frederic Bornancin, Denis Eichlisberger, Bruno Cenni
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Journal of Neuroinflammation
Subjects:
Multiple sclerosis
BTK
Remibrutinib
LOU064
Autoimmunity
Neuroinflammation
Online Access:https://doi.org/10.1186/s12974-023-02877-9

Internet

https://doi.org/10.1186/s12974-023-02877-9

Similar Items